The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
Hosted on MSN5d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
“Hopefully, this approval by the FDA shows that there is sufficient evidence for esketamine working that providers and patients and their families will be comfortable and more confident that in ...
Boing Boing on MSN13d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.
HealthDay on MSN14d
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionApproval of Spravato, granted following FDA priority review, was based on the results of ... Spravato targets the neurotransmitter glutamate; however, the mechanism by which esketamine exerts its ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback